Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab ( 20 mg/kg ) plus paclitaxel ( 200 mg/m ( 2 ) ) and carboplatin ( area under the concentration-time curve , 6 mg min/mL ) or paclitaxel and carboplatin alone once every 3 weeks for up to six cycles .
